40 related articles for article (PubMed ID: 38629072)
1. Intratumoral Cell Neighborhoods Coordinate Outcomes in Pancreatic Ductal Adenocarcinoma.
Wattenberg MM; Colby S; Garrido-Laguna I; Xue Y; Chang R; Delman D; Lee J; Affolter K; Mulvihill SJ; Beg MS; Wang-Gillam A; Wade JL; Guthrie KA; Chiorean EG; Ahmad SA; Lowy AM; Philip PA; Sohal DPS; Beatty GL
Gastroenterology; 2024 Jun; 166(6):1114-1129. PubMed ID: 38244727
[TBL] [Abstract][Full Text] [Related]
2. Impact of intratumoral microbiome on tumor immunity and prognosis in human pancreatic ductal adenocarcinoma.
Abe S; Masuda A; Matsumoto T; Inoue J; Toyama H; Sakai A; Kobayashi T; Tanaka T; Tsujimae M; Yamakawa K; Gonda M; Masuda S; Uemura H; Kohashi S; Inomata N; Nagao K; Harada Y; Miki M; Irie Y; Juri N; Ko T; Yokotani Y; Oka Y; Ota S; Kanzawa M; Itoh T; Imai T; Fukumoto T; Hara E; Kodama Y
J Gastroenterol; 2024 Mar; 59(3):250-262. PubMed ID: 38242997
[TBL] [Abstract][Full Text] [Related]
3. Unraveling Pancreatic Ductal Adenocarcinoma Immune Prognostic Signature through a Naive B Cell Gene Set.
Zhang S; Ta N; Zhang S; Li S; Zhu X; Kong L; Gong X; Guo M; Liu Y
Cancer Lett; 2024 May; ():216981. PubMed ID: 38795761
[TBL] [Abstract][Full Text] [Related]
4. Enhanced Complement Expression in the Tumor Microenvironment Following Neoadjuvant Therapy: Implications for Immunomodulation and Survival in Pancreatic Ductal Adenocarcinoma.
Zhang X; Lan R; Liu Y; Pillarisetty V; Li D; Zhao C; Sarkar S; Liu W; Hanna I; Gupta M; Hajdu C; Melamed J; Shusterma M; Widmer J; Allendorf J; Liu YZ
Res Sq; 2024 May; ():. PubMed ID: 38798691
[TBL] [Abstract][Full Text] [Related]
5. Multiplexed Imaging Mass Cytometry Analysis Characterizes the Vascular Niche in Pancreatic Cancer.
Sussman J; Kim NY; Kemp SB; Traum D; Katsuda T; Kahn BM; Xu J; Kim IK; Eskandarian C; Delman D; Beatty GL; Kaestner KH; Simpson AL; Stanger BZ
Cancer Res; 2024 May; ():. PubMed ID: 38695869
[TBL] [Abstract][Full Text] [Related]
6. Multiomics integration reveals NETosis heterogeneity and TLR2 as a prognostic biomarker in pancreatic cancer.
Fu Y; Tao J; Gu Y; Liu Y; Qiu J; Su D; Wang R; Luo W; Liu T; Zhang F; Zhang T; Zhao Y
NPJ Precis Oncol; 2024 May; 8(1):109. PubMed ID: 38769374
[TBL] [Abstract][Full Text] [Related]
7. Evolutionary and immune microenvironment dynamics during neoadjuvant treatment of oesophagael adenocarcinoma.
Barroux M; Househam J; Lakatos E; Ronel T; Baker AM; Salié H; Mossner M; Smith K; Kimberley C; Nowinski S; Berner A; Gunasri V; Jansen M; Caravagna G; Steiger K; Slotta-Huspenina J; Weichert W; Alberstmeier M; Chain B; Friess H; Bengsch B; Schmid R; Siveke J; Quante M; Graham T
Res Sq; 2023 Apr; ():. PubMed ID: 37090678
[TBL] [Abstract][Full Text] [Related]
8. Pancreatic cancer: Emerging field of regulatory B-cell-targeted immunotherapies.
Senturk ZN; Akdag I; Deniz B; Sayi-Yazgan A
Front Immunol; 2023; 14():1152551. PubMed ID: 37033931
[TBL] [Abstract][Full Text] [Related]
9. Translational and oncologic significance of tertiary lymphoid structures in pancreatic adenocarcinoma.
Gao Z; Azar J; Zhu H; Williams-Perez S; Kang SW; Marginean C; Rubinstein MP; Makawita S; Lee HS; Camp ER
Front Immunol; 2024; 15():1324093. PubMed ID: 38361928
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemotherapy is associated with suppression of the B cell-centered immune landscape in pancreatic ductal adenocarcinoma.
Rupp L; Dietsche I; Kießler M; Sommer U; Muckenhuber A; Steiger K; van Eijck CWF; Richter L; Istvanffy R; Jäger C; Friess H; van Eijck CHJ; Demir IE; Reyes CM; Schmitz M
Front Immunol; 2024; 15():1378190. PubMed ID: 38629072
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant Therapy Remodels the Pancreatic Cancer Microenvironment via Depletion of Protumorigenic Immune Cells.
Mota Reyes C; Teller S; Muckenhuber A; Konukiewitz B; Safak O; Weichert W; Friess H; Ceyhan GO; Demir IE
Clin Cancer Res; 2020 Jan; 26(1):220-231. PubMed ID: 31585935
[TBL] [Abstract][Full Text] [Related]
12. Germinal center reactions in tertiary lymphoid structures associate with neoantigen burden, humoral immunity and long-term survivorship in pancreatic cancer.
J Gunderson A; Rajamanickam V; Bui C; Bernard B; Pucilowska J; Ballesteros-Merino C; Schmidt M; McCarty K; Philips M; Piening B; Dubay C; Medler T; Newell P; Hansen P; Tran E; Tang E; Bifulco C; Crittenden M; Gough M; Young KH
Oncoimmunology; 2021 Mar; 10(1):1900635. PubMed ID: 33796412
[TBL] [Abstract][Full Text] [Related]
13. Tertiary lymphoid structures predict survival and response to neoadjuvant therapy in locally advanced rectal cancer.
Wang Q; Zhong W; Shen X; Hao Z; Wan M; Yang X; An R; Zhu H; Cai H; Li T; Lv Y; Dong X; Chen G; Liu A; Du J
NPJ Precis Oncol; 2024 Mar; 8(1):61. PubMed ID: 38431733
[TBL] [Abstract][Full Text] [Related]
14. Pancreatic Cancer Chemotherapy Is Potentiated by Induction of Tertiary Lymphoid Structures in Mice.
Delvecchio FR; Fincham REA; Spear S; Clear A; Roy-Luzarraga M; Balkwill FR; Gribben JG; Bombardieri M; Hodivala-Dilke K; Capasso M; Kocher HM
Cell Mol Gastroenterol Hepatol; 2021; 12(5):1543-1565. PubMed ID: 34252585
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of CD20 Positive B-Cells and B-Cell Aggregates in the Tumor Infiltration Zone is Associated with Better Survival of Patients with Pancreatic Ductal Adenocarcinoma.
Brunner M; Maier K; Rümmele P; Jacobsen A; Merkel S; Benard A; Krautz C; Kersting S; Grützmann R; Weber GF
Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32150869
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
